End point | Early outcomes (48 h) | In-hospital outcomes | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Beta-blocker (n = 93) | No beta-blocker (n = 99) | Crude RR (95% CI) | P value | Adjusted RRa (95% CI) | P value | Beta-blocker (n = 93) | No beta-blocker (n = 99) | Crude RR (95% CI) | P value | Adjusted RRa (95% CI) | P value | |
Primary composite outcomeb | 24 (26%) | 32 (32%) | 0.80 (0.51–1.25) | 0.32 | 0.94 (0.59–1.50) | 0.80 | 47 (51%) | 52 (53%) | 0.96 (0.73–1.27) | 0.78 | 1.14 (0.85–1.53) | 0.38 |
All-cause mortality | 7 (8%) | 18 (18%) | 0.41 (0.18–0.95) | 0.03 | – | – | 34 (37%) | 42 (42%) | 0.86 (0.61–1.23) | 0.41 | 1.05 (0.70–1.58) | 0.81 |
Resuscitated cardiac arrest or death | 8 (8%) | 22 (22%) | 0.39 (0.18–0.83) | 0.01 | – | – | 35 (38%) | 46 (46%) | 0.81 (0.58–1.13) | 0.22 | 0.93 (0.63–1.37) | 0.72 |
Mechanical circulatory support or cardiac transplant | 9 (10%) | 8 (8%) | 1.20 (0.48–2.97) | 0.70 | – | – | 14 (15%) | 11 (11%) | 1.35 (0.65–2.83) | 0.42 | 1.66 (0.77–3.59) | 0.20 |
Non-fatal myocardial infarction | 0 (0%) | 0 (0%) | – | – | – | – | 0 (0%) | 1 (1%) | – | 1.00c | – | – |
Transient ischemic attack or stroke | 0 (0%) | 0 (0%) | – | – | – | – | 0 (0%) | 3 (3%) | – | 0.25c | – | – |
Initiation of renal replacement therapy | 13 (14%) | 11 (11%) | 1.26 (0.59–2.67) | 0.55 | – | – | 22 (24%) | 15 (15%) | 1.56 (0.86–2.82) | 0.14 | 1.73 (0.93–3.20) | 0.08 |